Instil Bio, Inc. (TIL) shareholders
TILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.24−0.07 (-1.11%)
Close on Nov 12, 2026Market cap $42.32MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
29.5%
2M of 7M shares
Institutional holders
25
5 new, 10 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bronson Crouch Joint filing with Sb2a LP (31.00%), SB2A Management LLC (31.00%) and 3 more | 2,537,498 | 36.80% | 13D (active) amendment | Aug 6, 2022 |
| BML Investment Partners, L.P. | 645,600 | 9.50% | 13G (passive) amendment | Dec 31, 2025 |
| Leonard Braden Michael Joint filing with BML Investment Partners, L.P. (6.10%) | 440,000 | 6.70% | 13G (passive) amendment | Dec 31, 2024 |
| Boxer Capital, LLC Joint filing with Boxer Asset Management Inc. (5.50%), Joe Lewis (5.50%) | 355,500 | 5.50% | 13G (passive) | Sep 18, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TIL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 645,600 | 9.52% | $4.96M | – | 2.82% |
| Vivo Capital, LLC | 292,743 | 4.32% | $2.25M | – | 0.21% |
| Kalehua Capital Management LLC | 199,200 | 2.94% | $1.53M | −123,679 | 0.49% |
| UBS Group AG | 177,423 | 2.62% | $1.36M | +171,045 | 0.00% |
| Vanguard Capital Management LLC | 163,738 | 2.41% | $1.26M | −10,845 | 0.00% |
| Millennium Management LLC | 134,575 | 1.98% | $1.03M | +1,629 | 0.00% |
| BlackRock, Inc. | 55,504 | 0.82% | $426.83K | +3,486 | 0.00% |
| Renaissance Technologies LLC | 50,300 | 0.74% | $386.81K | −8,800 | 0.00% |
| Nomura Asset Management International Inc. | 50,000 | 0.74% | $385.00K | – | 0.00% |
| Jacobs Levy Equity Management, Inc | 43,051 | 0.63% | $331.06K | New | 0.00% |
| Geode Capital Management, LLC | 42,234 | 0.62% | $324.92K | −6,777 | 0.00% |
| LPL Financial LLC | 32,075 | 0.47% | $246.65K | +12 | 0.00% |
| Citadel Advisors LLC | 30,639 | 0.45% | $235.61K | −7,923 | 0.00% |
| Vanguard Fiduciary Trust Co | 22,773 | 0.34% | $175.12K | +148 | 0.00% |
| State Street Corp | 17,595 | 0.26% | $135.31K | – | 0.00% |
| Americana Partners, LLC | 16,176 | 0.24% | $124.39K | – | 0.00% |
| Dimensional Fund Advisors LP | 15,761 | 0.23% | $121.13K | −4,214 | 0.00% |
| Morgan Stanley | 11,934 | 0.18% | $91.77K | −7,887 | 0.00% |
| Vanguard Global Advisers, LLC | 1,470 | 0.02% | $11.30K | – | 0.00% |
| Northwestern Mutual Wealth Management Co | 550 | 0.01% | $4.23K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 25 | 2M | 29.5% | 5 / 5 | 8 / 10 | 0M | 0M |
| Q1 2026 | 31 | 2M | 35.9% | 10 / 4 | 8 / 6 | 1M | 1M |
| Q4 2025 | 28 | 3M | 37.5% | 6 / 7 | 8 / 11 | 0M | 0M |
| Q3 2025 | 33 | 3M | 39.2% | 5 / 8 | 10 / 9 | 0M | 0M |
| Q2 2025 | 37 | 3M | 40.6% | 9 / 7 | 13 / 12 | 0M | 1M |
| Q1 2025 | 42 | 3M | 49.4% | 9 / 11 | 12 / 6 | 1M | 1M |
| Q4 2024 | 39 | 3M | 49.2% | 9 / 19 | 3 / 18 | 1M | 1M |
| Q3 2024 | 48 | 3M | 50.5% | 28 / 5 | 8 / 8 | 2M | 1M |
| Q2 2024 | 29 | 2M | 36.2% | 3 / 8 | 8 / 4 | 0M | 0M |
| Q1 2024 | 30 | 2M | 34.8% | 5 / 5 | 13 / 4 | 0M | 0M |
| Q4 2023 | 29 | 2M | 32.0% | 29 / 0 | 0 / 0 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
28 funds held TIL in Q1 2026, 58% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TIL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 118,992 | 1.75% | $915.05K | 0.00% | Jun 30, 2026 |
| Nomura Healthcare Fund | 50,000 | 0.74% | $384.50K | 0.05% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 41,589 | 0.61% | $319.82K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 22,689 | 0.33% | $183.10K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 12,849 | 0.19% | $98.81K | 0.01% | Jun 30, 2026 |
| T. Rowe Price Extended Equity Market Index Fund | 8,700 | 0.13% | $66.90K | 0.01% | Jun 30, 2026 |
| Avantis U.S. Small Cap Equity ETF | 7,492 | 0.11% | $60.46K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 6,775 | 0.10% | $54.67K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 6,653 | 0.10% | $47.37K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 5,377 | 0.08% | $43.39K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 3,216 | 0.05% | $25.95K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 3,157 | 0.05% | $24.28K | 0.00% | Jun 30, 2026 |
| Schwab Total Stock Market Index Fund | 2,981 | 0.04% | $21.22K | 0.00% | Jul 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 1,385 | 0.02% | $9.86K | 0.00% | Jul 31, 2026 |
| U.S. Core Equity 1 Portfolio | 1,052 | 0.02% | $7.49K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bronson Crouch | CEO and Chairman, Director, 10% owner | 41,036,671 | 605.08% | Apr 28, 2025 |
| Sandeep Laumas | CFO and CBO | 3,212,460 | 47.37% | Sep 12, 2025 |
| Gwendolyn Binder | Director | – | – | Jun 12, 2026 |
| Neil W. Gibson | Director | – | – | Jun 12, 2026 |
| R. Kent McGaughy Jr | Director | 8,218,467 | 121.18% | Jun 12, 2026 |
| George Matcham | Director | 762,000 | 11.24% | Jun 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sandeep Laumas CFO and CBO | Sep 10, 2025 | Sale | −17,539 | $23.04 | $404.10K | 12,461 |
| Sandeep Laumas CFO and CBO | Sep 10, 2025 | Sale | −12,461 | $23.88 | $297.57K | 0 |
| Sandeep Laumas CFO and CBO | Sep 10, 2025 | Option exercise | +13,000 | $12.68 | $164.84K | 30,000 |
| Sandeep Laumas CFO and CBO | Sep 10, 2025 | Option exercise | +17,000 | $11.60 | $197.20K | 17,000 |
| R. Kent McGaughy Jr Director | Mar 15, 2022 | Other | −260,323 | – | – | 8,218,467 |
| R. Kent McGaughy Jr Director | Mar 23, 2021 | Conversion | +954,182 | – | – | 8,028,790 |
| R. Kent McGaughy Jr Director | Mar 23, 2021 | Conversion | +7,074,608 | – | – | 7,074,608 |
| R. Kent McGaughy Jr Director | Mar 23, 2021 | Buy | +450,000 | $20.00 | $9.00M | 8,478,790 |
| Bronson Crouch CEO and Chairman, Director, 10% owner | Mar 23, 2021 | Conversion | +6,098,799 | – | – | 36,098,799 |
| Bronson Crouch CEO and Chairman, Director, 10% owner | Mar 23, 2021 | Conversion | +30,000,000 | – | – | 30,000,000 |
| Bronson Crouch CEO and Chairman, Director, 10% owner | Mar 23, 2021 | Conversion | +1,431,274 | – | – | 37,530,073 |
| Bronson Crouch CEO and Chairman, Director, 10% owner | Mar 23, 2021 | Buy | +450,000 | $20.00 | $9.00M | 37,980,073 |
| Jack Nielsen Director | Mar 23, 2021 | Conversion | +11,709,696 | – | – | 11,709,696 |
| Jack Nielsen Director | Mar 23, 2021 | Buy | +300,000 | $20.00 | $6.00M | 12,486,787 |
| Jack Nielsen Director | Mar 23, 2021 | Conversion | +477,091 | – | – | 12,186,787 |
| Ventures V. LLC Curative 10% owner | Mar 23, 2021 | Conversion | +1,431,274 | – | – | 37,530,073 |
| Ventures V. LLC Curative 10% owner | Mar 23, 2021 | Conversion | +6,098,799 | – | – | 36,098,799 |
| Ventures V. LLC Curative 10% owner | Mar 23, 2021 | Conversion | +30,000,000 | – | – | 30,000,000 |
| Ventures V. LLC Curative 10% owner | Mar 23, 2021 | Buy | +450,000 | $20.00 | $9.00M | 37,980,073 |
| Vivo Capital Fund IX, L.P. 10% owner | Mar 23, 2021 | Buy | +300,000 | $20.00 | $6.00M | 12,486,787 |
| Vivo Capital Fund IX, L.P. 10% owner | Mar 23, 2021 | Conversion | +477,091 | – | – | 12,186,787 |
| Vivo Capital Fund IX, L.P. 10% owner | Mar 23, 2021 | Conversion | +11,709,696 | – | – | 11,709,696 |
| Nimish P. Shah Director | Mar 23, 2021 | Buy | +48,390 | $20.00 | $967.80K | 48,390 |
| Nimish P. Shah Director | Mar 23, 2021 | Buy | +116,880 | $20.00 | $2.34M | 597,596 |
| Nimish P. Shah Director | Mar 23, 2021 | Buy | +10,470 | $20.00 | $209.40K | 563,533 |
| Nimish P. Shah Director | Mar 23, 2021 | Buy | +19,620 | $20.00 | $392.40K | 19,620 |
| Nimish P. Shah Director | Mar 23, 2021 | Buy | +104,640 | $20.00 | $2.09M | 5,635,937 |
| Nimish P. Shah Director | Mar 23, 2021 | Conversion | +480,716 | – | – | 480,716 |
| Nimish P. Shah Director | Mar 23, 2021 | Conversion | +43,033 | – | – | 553,063 |
| Nimish P. Shah Director | Mar 23, 2021 | Conversion | +430,431 | – | – | 5,531,297 |
| Nimish P. Shah Director | Mar 23, 2021 | Conversion | +510,030 | – | – | 510,030 |
| Nimish P. Shah Director | Mar 23, 2021 | Conversion | +5,100,866 | – | – | 5,100,866 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
2.67%
0M shares short
Days to cover
2.3
At 0M shares a day
Change since last report
+6.3%
From 0M shares
Short volume, 20 days
34.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Instil Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 25,099 shares on Sep 22, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Sandeep Laumas Officer | Sep 10, 2025 | 30,000 | $701.60K | Sep 10, 2025 | Stock Option Exercise |
See a number that looks wrong?